Orris

Essay on pathophysiology of bleeding in dengue

Reading File
Finding Sources
Searching PubMed

dengue hemorrhage thrombocytopenia pathophysiology

Searching the Web

pathophysiology of bleeding in dengue fever thrombocytopenia coagulopathy vascular leak 2024

Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading Article
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
I now have comprehensive information from multiple authoritative sources. Let me compile the essay.

Pathophysiology of Bleeding in Dengue

Introduction

Dengue is a mosquito-borne flaviviral infection caused by four antigenically distinct serotypes (DENV-1 to DENV-4), transmitted principally by Aedes aegypti. It infects an estimated 390 million people annually, with 100 million symptomatic cases and approximately 40,000 deaths from severe dengue. Bleeding is a hallmark of severe disease, ranging from minor petechiae and epistaxis to catastrophic gastrointestinal hemorrhage. The hemorrhagic diathesis in dengue is not explained by any single mechanism; rather, it arises from the convergence of three interacting pathophysiological processes: thrombocytopenia, endothelial dysfunction with plasma leakage, and coagulopathy. Superimposed on all three is the immunological phenomenon of antibody-dependent enhancement (ADE), which amplifies viral replication and drives the cytokine storm that underlies severe disease.

1. The Immune Substrate: Antibody-Dependent Enhancement

To understand bleeding in dengue, one must first understand why secondary infection with a heterologous serotype is so much more severe than primary infection. Infection with any one serotype elicits lifelong homotypic immunity but also generates cross-reactive, non-neutralizing antibodies against the other three serotypes. When the individual encounters a second serotype, these pre-existing antibodies bind the new virions but fail to neutralize them. Instead, the opsonized virus–antibody complexes enter monocytes and macrophages via Fc receptors, a process termed antibody-dependent enhancement. This dramatically increases intracellular viral load in mononuclear phagocytes — the very cells that govern cytokine responses — and drives the release of massive quantities of TNF-α, IL-6, IL-8, IL-10, and other inflammatory mediators (Harrison's Principles of Internal Medicine 22e; Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 336).
A recently identified molecular contributor is a population of non-neutralizing, fucosylated IgG1 antibodies that bind the activating Fc receptor FcγRIIIA and cross-react with platelet surface antigens. These antibodies directly link immune enhancement with platelet destruction, bridging the ADE hypothesis with the thrombocytopenia central to hemorrhage — Dermatology: 2-Volume Set 5e, p. 1729.

2. Thrombocytopenia: The Primary Cause of Bleeding Tendency

Thrombocytopenia (platelet count <100,000/μL in ~50% of symptomatic cases) is the most clinically visible hematological abnormality and the most direct contributor to bleeding. Its pathogenesis is multifactorial, involving both reduced platelet production and accelerated peripheral destruction.

2.1 Reduced Production: Bone Marrow Suppression

DENV infects megakaryocyte progenitor cells and stromal cells in the bone marrow, causing direct cytopathic injury and transient myelosuppression. Suppression of hematopoiesis contributes to falling platelet counts from early in the febrile phase. This mechanism is also responsible for the leukopenia and lymphopenia that accompany dengue and explains the characteristic "bone pain" of classic dengue fever, reflecting active viral replication in bone marrow cells — (Goldman-Cecil Medicine, p. 1538; Emedicine/Medscape).

2.2 Increased Peripheral Destruction: Immune-Mediated Mechanisms

Peripheral platelet destruction operates via multiple overlapping pathways:
  • Molecular mimicry: DENV non-structural protein 1 (NS1) shares epitopes with platelet surface glycoproteins. Anti-NS1 antibodies cross-react with platelets, triggering antibody-mediated platelet clearance by the reticuloendothelial system.
  • Complement activation: Dengue-induced immune complexes activate the complement cascade. Complement deposition on platelet surfaces promotes their phagocytosis and lysis.
  • Fucosylated IgG1 antibodies: As noted above, these bind FcγRIIIA on platelets and macrophages, directly promoting platelet destruction and simultaneously amplifying macrophage activation.
  • Platelet–virus interaction: DENV can directly infect platelets, inducing platelet apoptosis and aggregation, thereby reducing circulating numbers while paradoxically promoting local microvascular thrombosis.
  • Platelet dysfunction: Even those platelets that remain in circulation exhibit profound dysfunction — impaired aggregation response, reduced thromboxane generation, and abnormal activation — further compromising primary hemostasis independently of the absolute platelet count.
The severity of thrombocytopenia correlates closely with clinical severity; platelet counts below 20,000/μL are associated with the greatest risk of spontaneous hemorrhage — (Red Book 2021; Cherie et al., Viruses 2024, PMID 39066252).

3. Endothelial Dysfunction and Vascular Fragility

3.1 Plasma Leakage Syndrome

The critical and defining feature of severe dengue (dengue hemorrhagic fever) is increased capillary permeability, resulting in the extravasation of plasma proteins and fluid into the interstitial and serosal compartments. This manifests as hemoconcentration (hematocrit rise ≥20% from baseline), pleural effusions, ascites, and hypovolemic shock. The plasma leakage phase typically lasts 24–48 hours, coinciding with defervescence on days 3–7 — the "critical phase" — (Red Book 2021, p. 521; Goldman-Cecil Medicine, p. 1543).
The molecular basis involves:
  • Cytokine-mediated endothelial injury: TNF-α, IL-6, IL-8, and C5a released from dengue-infected monocytes and T-cells disrupt endothelial tight junctions and activate endothelial cells, increasing expression of adhesion molecules and reducing barrier function.
  • Direct DENV infection of endothelial cells: The virus infects endothelial cells, inducing apoptosis and loss of barrier integrity without causing overt cell death in early infection, a mechanism that allows plasma leakage to occur without frank vascular necrosis.
  • NS1 antigenemia: Secreted NS1 protein directly disrupts endothelial glycocalyx integrity and activates toll-like receptor 4 (TLR4), increasing vascular permeability. NS1 also activates complement locally at the endothelial surface, amplifying this process.
  • Histamine and VEGF release: Mast cell degranulation (triggered by dengue-activated immune cells) releases histamine and VEGF, both of which are potent vasodilators and permeability-enhancing agents.

3.2 Vascular Fragility and Hemorrhagic Tendency

Increased capillary fragility, demonstrated clinically by the tourniquet (Rumpel-Leede) test (>20 petechiae per 2.5×2.5 cm² area, positive in over 50% of severe cases), reflects endothelial damage rather than thrombocytopenia alone. Even patients with modest thrombocytopenia may exhibit significant petechiae due to structural endothelial compromise. Bleeding from the skin (petechiae, ecchymoses, purpura), mucosae (gingival bleeding, epistaxis), and internal organs (GI hemorrhage) results from the combined effect of vascular fragility and inadequate primary hemostasis — (Brenner and Rector's The Kidney, p. 3526).

4. Coagulopathy and Disseminated Intravascular Coagulation

In severe dengue, secondary coagulopathy develops, extending the hemorrhagic tendency beyond simple thrombocytopenia.

4.1 Mechanisms of Coagulopathy

  • Hepatocyte injury: DENV infects hepatocytes, causing dengue hepatitis with elevation of transaminases (AST/ALT commonly several hundred, occasionally >1000 IU/L). Impaired hepatic synthesis of clotting factors (II, V, VII, IX, X, fibrinogen) prolongs prothrombin time (PT) and activated partial thromboplastin time (aPTT), creating a secondary coagulopathy.
  • Cytokine-driven tissue factor expression: TNF-α and IL-1β upregulate tissue factor on monocytes and endothelial cells, activating the extrinsic coagulation pathway and initiating consumptive coagulopathy.
  • Elevated PAI-1 (Plasminogen Activator Inhibitor-1): Dengue infection elevates PAI-1, a procoagulant that inhibits fibrinolysis and promotes fibrin accumulation in microvessels.

4.2 Disseminated Intravascular Coagulation (DIC)

In the most severe cases, uncontrolled coagulation system activation leads to DIC, characterized by:
  • Widespread microvascular fibrin thrombi → multi-organ ischemia
  • Consumptive depletion of clotting factors and fibrinogen → coagulopathic hemorrhage
  • Elevated fibrin degradation products (FDPs) and D-dimer
  • Low fibrinogen levels
DIC in dengue thus causes simultaneous thrombosis and hemorrhage — a paradox that explains why some patients develop both hemorrhagic manifestations and ischemic end-organ injury. Prolonged aPTT has been identified as an independent predictor of AKI in dengue — (Brenner and Rector's The Kidney, p. 3527; Emedicine/Medscape).

5. Integration: The Bleeding Diathesis in Clinical Context

The three pathophysiological streams converge during the critical phase of dengue:
MechanismContribution to Bleeding
Thrombocytopenia (↓ production + ↑ destruction)Impaired primary hemostasis
Platelet dysfunctionFurther impairment of platelet plug formation
Endothelial damage / vascular fragilityLeakage and petechiae at capillary level
Plasma leakage / hemoconcentrationShock; tissue hypoperfusion worsens coagulopathy
Hepatic injury → ↓ clotting factor synthesisImpaired secondary hemostasis
Tissue factor → extrinsic pathway activationDIC
DIC → consumptive coagulopathySystemic hemorrhage + microthrombosis
Elevated PAI-1Impaired fibrinolysis → fibrin accumulation

6. Clinical Spectrum of Bleeding

  • Minor hemorrhagic manifestations (dengue without warning signs): petechiae, positive tourniquet test, epistaxis, gingival bleeding
  • Mucosal bleeding (dengue with warning signs): indicates progression toward severe disease
  • Severe/clinically significant bleeding: hematemesis, melena, hematuria, menorrhagia, intracranial hemorrhage — these mandate immediate inpatient management and constitute a criterion for Group C (severe dengue) classification under the 2009 WHO system (Red Book 2021, p. 482)

7. Summary

Bleeding in dengue arises from a triad of thrombocytopenia, vascular endothelial dysfunction, and coagulopathy, each amplified by the immunopathological response to DENV infection — particularly in ADE-mediated secondary infection. The cytokine storm driven by ADE is the master regulator: it simultaneously suppresses megakaryopoiesis, destroys platelets via immune mechanisms, disrupts endothelial barrier function, activates coagulation, and injures the liver. NS1 antigenemia adds a direct endothelial-disruptive element. DIC represents the extreme end of the coagulopathy spectrum, where the system's attempt to contain infection through coagulation paradoxically consumes its own hemostatic machinery and produces both thrombosis and hemorrhage. Recognition of this complex, multi-mechanistic pathophysiology is essential for rational clinical management — which centers on fluid resuscitation, avoidance of antiplatelet and anticoagulant drugs, selective use of blood products only for significant active bleeding, and vigilant monitoring through the critical phase.
Key Sources:
  • Goldman-Cecil Medicine, p. 1536–1550
  • Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 336
  • Red Book 2021 (Committee on Infectious Diseases), pp. 520–529
  • Brenner and Rector's The Kidney, p. 3526–3527
  • Andrews' Diseases of the Skin / Dermatology 5e, p. 1729
  • Harrison's Principles of Internal Medicine 22e, p. 3901
  • Cherie TJJ et al. "Immuno-Haematologic Aspects of Dengue Infection." Viruses 2024 [PMID: 39066252]
  • Ghorai T et al. "Role of auto-antibodies in dengue pathogenesis." Arch Microbiol 2024 [PMID: 38616229]
This is a shared conversation. Sign in to Orris to start your own chat.